Verona pharma to present additional analyses of the phase 3 enhance studies in copd at ers international congress 2025

Posters support ohtuvayre ® (ensifentrine) as a first-in-class selective dual inhibitor of pde3 and pde4 for a broad copd population
VRNA Ratings Summary
VRNA Quant Ranking